Occupational Exposure Limits for Active Pharmaceutical Ingredients: A Comparative Review of ICH Q3C, OSHA, NIOSH, and European Medicines Agency Regulatory Frameworks and their Implications for Worker Health Surveillance
Year: 2026
Type: article
Abstract: Active Pharmaceutical Ingredients (APIs) pose a significant occupational health challenge in pharmaceutical manufacturing and healthcare settings, where workers involved in synthesis, formulation, packaging, dispensing, and administration may be exposed to pharmacologically potent substances. Occupational Exposure Limits (OELs) are essential for protecting workers from unintended biological effects. This review critically evaluates four regulatory frameworks relevant to pharmaceutical occupational exposure: ICH Q3C on residual solvents, Occupational Safety and Health Administration (OSHA) Permissible Exposure Limits (PELs), National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Limits (RELs), and the European Medicines Agency (EMA) guideline for health-based exposure limits (HBELs). Their scientific foundations, derivation methodologies, applicability, legal status, and implications for occupational health surveillance were compared. A literature search was conducted using PubMed, Scopus, Web of Science, and regulatory databases, including OSHA, NIOSH, EMA, ICH, and ISPE, covering publications from 1990 to 2024. Studies addressing OEL derivation, occupational exposure assessment, worker health outcomes, and regulatory compliance were narratively synthesised. Considerable heterogeneity was identified among frameworks regarding scientific basis, methodology, update frequency, and enforceability. ICH Q3C provides classifications and permitted daily exposure limits for residual solvents but is not specifically designed for API dust. OSHA PELs is legally enforceable but include numerous limits that have not been comprehensively updated. NIOSH RELs incorporate scientific evidence but are generally advisory. EMA HBEL methodology offers an API-specific approach based on pharmacological and toxicological evaluation, although its primary regulatory purpose is prevention of cross-contamination. Occupational Exposure Banding (OEB) approaches, including ISPE systems, provide practical support where substance-specific OELs are unavailable. Overall, no single framework fully addresses pharmaceutical occupational health needs. Greater international harmonisation, periodic review, exposure monitoring, and health surveillance are needed to strengthen worker protection. Major Findings: Regulatory frameworks differ substantially in scope, legal status, and scientific basis for API occupational exposure. EMA HBEL/PDE, NIOSH, and ISPE OEB approaches provide complementary tools, but no single framework fully addresses worker protection. An integrated OEL/OEB-based exposure assessment, biological monitoring, and proportional health surveillance framework is proposed.
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7220912468